<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641794</url>
  </required_header>
  <id_info>
    <org_study_id>DN-DN1406131-101</org_study_id>
    <nct_id>NCT03641794</nct_id>
  </id_info>
  <brief_title>Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers</brief_title>
  <official_title>A Phase I Study of DN1406131 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai De Novo Pharmatech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind Phase I study to evaluate the safety, tolerability, and
      pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to
      inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and tryptophan 2,3-Dioxygenase 2
      (TDO-2) and help the human immune system attack solid tumor cells more effectively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events - type, incidence, severity</measure>
    <time_frame>28 day</time_frame>
    <description>Evaluate the safety and toxicity of DN1406131 in healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>14 day</time_frame>
    <description>To define the Maximum Tolerated Dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum for biomarkers of IDO activity (kynurenine and tryptophan)</measure>
    <time_frame>48 hours</time_frame>
    <description>Evaluation of serum for biomarkers of IDO activity (kynurenine and tryptophan), before and after initiation of therapy.
Pharmacodynamics（PD）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>48 hours</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak time</measure>
    <time_frame>48 hours</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>DN1406131</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DN1406131</intervention_name>
    <description>IDO1 and TDO2 inhibitor</description>
    <arm_group_label>DN1406131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater of 18 years and less than 45

          -  Weight ≥50 kg,body mass index of 19~26 kg/m2

          -  Signed ICF

        Exclusion Criteria:

          -  active autoimmune disease

          -  uncontrolled concurrent illness

          -  Smoking

          -  Drugs

          -  positive serology for HIV, Hepatitis B or C,Syphilis

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qinghong Zhou</last_name>
    <role>Study Director</role>
    <affiliation>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanwan Ji</last_name>
    <phone>18852605644</phone>
    <email>jiwanwan@sh-qingfeng.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shunpeng Hu</last_name>
    <phone>+86 13683002413</phone>
    <email>hushunpeng@sh-qingfeng.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PKUCare Luzhong Hospital</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>255000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

